Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Acquisitions & Divestments (2022 - 2025)

10x Genomics' Change in Acquisitions & Divestments history spans 4 years, with the latest figure at $125.2 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments changed N/A year-over-year to $125.2 million; the TTM value through Dec 2025 reached $125.2 million, up 385.61%, while the annual FY2025 figure was $125.2 million, 385.61% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $125.2 million at 10x Genomics, up from $22.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $125.2 million in Q4 2025 and bottomed at -$22.9 million in Q4 2022.
  • The 4-year median for Change in Acquisitions & Divestments is $16.0 million (2022), against an average of $22.5 million.
  • The largest annual shift saw Change in Acquisitions & Divestments soared 645.97% in 2023 before it plummeted 98.22% in 2024.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at -$22.9 million in 2022, then surged by 117.72% to $4.1 million in 2023, then surged by 447.53% to $22.2 million in 2024, then skyrocketed by 464.04% to $125.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Change in Acquisitions & Divestments are $125.2 million (Q4 2025), $22.2 million (Q3 2024), and $3.0 million (Q2 2024).